Company Filing History:
5 out of 3,923 
4 out of 96 
1 out of 18 Years Active: 2013-2020
Title: Andrew Griffin Sprague: Innovator in RNAi Therapeutics
Introduction
Andrew Griffin Sprague is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of organic compositions aimed at treating various diseases. With a total of 10 patents to his name, Sprague's work has the potential to impact the treatment of serious health conditions.
Latest Patents
Among his latest patents, Sprague has focused on organic compositions to treat Beta-ENaC-related diseases. These patents disclose RNAi agents that are useful in methods of treating conditions such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension. The innovative approach involves using a therapeutically effective amount of an RNAi agent to target Beta-ENaC.
Career Highlights
Sprague has worked with prominent companies in the pharmaceutical industry, including Novartis AG and Arrowhead Pharmaceuticals, Inc. His experience in these organizations has allowed him to develop and refine his innovative ideas in the field of RNA interference.
Collaborations
Throughout his career, Sprague has collaborated with esteemed colleagues such as Antonin De Fougerolles and John Louis Diener. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Andrew Griffin Sprague is a distinguished inventor whose work in RNAi therapeutics holds promise for treating various diseases. His contributions to the field are marked by a series of innovative patents and collaborations with leading professionals in the industry.